HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jing Yu Selected Research

3- chloro- 2- methyl- N- (4- (2- (4- methyl- 1- piperazinyl)- 2- oxoethyl)- 1,3- thiazol- 2- yl)benzenesulfonamide

1/2021Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
12/201811β-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy.
1/2012BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
1/2011Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity.
11/2008[Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jing Yu Research Topics

Disease

186Neoplasms (Cancer)
12/2022 - 11/2002
52Breast Neoplasms (Breast Cancer)
06/2022 - 03/2008
38Inflammation (Inflammations)
12/2022 - 01/2012
38Neoplasm Metastasis (Metastasis)
01/2022 - 08/2007
32Hypertension (High Blood Pressure)
01/2022 - 03/2005
28Infections
01/2022 - 06/2004
18Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2022 - 01/2011
18Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 05/2013
18Hepatocellular Carcinoma (Hepatoma)
12/2021 - 11/2005
17Body Weight (Weight, Body)
10/2021 - 06/2002
16Fibrosis (Cirrhosis)
05/2022 - 03/2007
16Pain (Aches)
01/2022 - 07/2011
15Wounds and Injuries (Trauma)
11/2022 - 01/2012
15Lung Neoplasms (Lung Cancer)
01/2022 - 08/2012
14Carcinogenesis
01/2022 - 05/2011
13Myocardial Infarction
01/2022 - 07/2004
12Esophageal Squamous Cell Carcinoma
01/2022 - 12/2017
12Infarction (Infarctions)
04/2021 - 07/2004
12Carcinoma (Carcinomatosis)
12/2020 - 11/2005
11Ischemia
01/2021 - 05/2004
10Stomach Neoplasms (Stomach Cancer)
04/2022 - 10/2016
10Insulin Resistance
01/2022 - 11/2008
10Atherosclerosis
10/2021 - 07/2009
10Glioma (Gliomas)
02/2021 - 01/2014
9Epilepsy (Aura)
10/2022 - 01/2007
9Obesity
01/2022 - 08/2007
9Heart Failure
01/2022 - 03/2013
9Type 2 Diabetes Mellitus (MODY)
09/2021 - 08/2007
9Reperfusion Injury
01/2021 - 05/2004
8Stroke (Strokes)
05/2022 - 01/2013
8COVID-19
01/2022 - 01/2020
8Colonic Neoplasms (Colon Cancer)
01/2022 - 09/2009
8Leukemia
12/2021 - 04/2014
8Hypoxia (Hypoxemia)
08/2021 - 04/2013
8Necrosis
05/2018 - 08/2004
7Lymphatic Metastasis
10/2022 - 02/2015
7Triple Negative Breast Neoplasms
05/2022 - 01/2017
7Cardiovascular Diseases (Cardiovascular Disease)
02/2022 - 03/2010
7Colitis
11/2021 - 01/2015
7Myocardial Ischemia (Ischemic Heart Diseases)
11/2021 - 05/2004
7Rectal Neoplasms (Rectal Cancer)
03/2019 - 07/2016
7Proliferative Vitreoretinopathy
01/2018 - 07/2010
7Neuralgia (Stump Neuralgia)
01/2017 - 01/2012
6Hemorrhage
01/2023 - 12/2007
6Diarrhea
04/2022 - 10/2016
6Melanoma (Melanoma, Malignant)
03/2022 - 04/2013
6Osteoporosis
02/2022 - 07/2008
6Fatigue
01/2022 - 09/2004
6Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 01/2014
6Esophageal Neoplasms (Esophageal Cancer)
01/2022 - 06/2011
6Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2021 - 10/2010

Drug/Important Bio-Agent (IBA)

53Proteins (Proteins, Gene)FDA Link
08/2022 - 10/2003
48Biomarkers (Surrogate Marker)IBA
12/2022 - 03/2007
33Pharmaceutical PreparationsIBA
01/2022 - 08/2008
29Biological ProductsIBA
01/2022 - 11/2005
23Messenger RNA (mRNA)IBA
09/2022 - 07/2008
23MicroRNAs (MicroRNA)IBA
01/2022 - 02/2011
20Glucose (Dextrose)FDA LinkGeneric
01/2021 - 11/2008
19Peptides (Polypeptides)IBA
01/2021 - 06/2004
18CytokinesIBA
01/2022 - 03/2008
16Long Noncoding RNAIBA
05/2022 - 07/2017
15HydrogelsIBA
01/2023 - 11/2013
14DNA (Deoxyribonucleic Acid)IBA
01/2022 - 10/2007
14Cisplatin (Platino)FDA LinkGeneric
06/2021 - 01/2009
13RNA (Ribonucleic Acid)IBA
05/2022 - 07/2008
13Therapeutic UsesIBA
05/2022 - 04/2007
13Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2022 - 02/2013
12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2020 - 07/2004
11LipidsIBA
07/2022 - 01/2011
11Small Interfering RNA (siRNA)IBA
05/2021 - 03/2008
10AntigensIBA
02/2022 - 02/2005
9Estrogens (Estrogen)FDA Link
05/2022 - 05/2004
9SolutionsIBA
01/2022 - 09/2005
9Transcription Factors (Transcription Factor)IBA
01/2022 - 01/2013
9EnzymesIBA
01/2022 - 03/2007
9Tyrosine Kinase InhibitorsIBA
01/2022 - 02/2015
8CholesterolIBA
07/2022 - 05/2012
8Circular RNAIBA
11/2021 - 04/2019
8Interleukin-6 (Interleukin 6)IBA
01/2020 - 07/2004
7Doxorubicin (Adriamycin)FDA LinkGeneric
12/2022 - 10/2007
7Analgesics (Analgesic Drugs)IBA
01/2022 - 01/2014
7VaccinesIBA
12/2021 - 11/2005
7Sevoflurane (Ultane)FDA LinkGeneric
01/2021 - 04/2010
6NF-kappa B (NF-kB)IBA
12/2022 - 08/2007
6Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 04/2013
6Antihypertensive Agents (Antihypertensives)IBA
01/2022 - 01/2018
6Interleukin-10 (Interleukin 10)IBA
11/2021 - 04/2013
6oxidized low density lipoproteinIBA
11/2021 - 01/2015
6Indicators and Reagents (Reagents)IBA
11/2021 - 01/2014
6ErbB Receptors (EGF Receptor)IBA
11/2021 - 01/2019

Therapy/Procedure

93Therapeutics
05/2022 - 04/2007
33Drug Therapy (Chemotherapy)
04/2022 - 11/2002
21Radiotherapy
02/2022 - 01/2011
16Immunotherapy
02/2022 - 07/2008
10Aftercare (After-Treatment)
05/2022 - 01/2011
10Precision Medicine
01/2022 - 11/2015
9Injections
01/2022 - 06/2002
8Neoadjuvant Therapy
04/2022 - 06/2015
8Lasers (Laser)
01/2021 - 04/2009
7Transplantation
01/2021 - 01/2012